Prescient is well funded as it looks to bring its novel OmniCAR T-cell therapy into clinical trials
With around $15m in the bank, Prescient is pressing ahead to move its novel OmniCAR...
With around $15m in the bank, Prescient is pressing ahead to move its novel OmniCAR...
Prescient’s OmniCAR platform could overcome the limitations of CAR-T treatments for cancer and it’s attracting...
Stockhead’s resident health and biotech expert Tim Boreham is putting down the microscope and picking up...
The appointment gives PTX a world-leading development team in the race to find solutions for...
Got 90 seconds? Then listen to CEO, Steven Yatomi-Clarke tell us about their company news....
Prescient Therapeutics (ASX:PTX) says its cancer-fighting drug candidate has exhibited an excellent safety in an...
The results significantly de-risk the project as PTX continues development of its OmniCAR platform. As...
Tragedy struck the CAR-T space this month with a US company halting a trial of...
Clinical stage oncology company Prescient Therapeutics (ASX:PTX) has announced another crucial step forward in the development of...
he federal government’s “patent box” initiative caught the eye of Australia’s biotech sector in Tuesday...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.